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Sciences and ChinesAbstract Granisetron showed one well-deﬁned reduction peak at Hanging Mercury Drop
Electrode (HMDE) in the potential range from 1.3 to 1.5 V due to reduction of C¼N bond.
Solid-phase extraction technique was employed for extraction of Granisetron from spiked human
plasma. Granisetron showed peak current enhancement of 4.45% at square-wave voltammetry and
5.33% at cyclic voltammetry as compared with the non stripping techniques. The proposed
voltammetric method allowed quantiﬁcation of Granisetron in pharmaceutical formulation over
the target concentration range of 50–200 ng/mL with detection limit 13.63 ng/mL, whereas in
human plasma 50–225 ng/mL with detection limit 11.75 ng/mL.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Nausea and vomiting are two of the most severe side effects of
cytotoxic chemotherapy or radiotherapy and prolonged vomiting
may also induce severe complications [1]. Granisetron (endo-ersity. Production and hosting by E
1 2442766;
.co.in (R. Jain).
tute of Materia Medica, Chinese
e Pharmaceutical Association.1-methyl-N-[9-methyl-9-azabicyclo (3.3.1) non-3-yl]-1H-indazole-
3-carboxamide) (Fig. 1) is a highly selective 5-hydroxytrypta-
mine 3 (5-HT3) receptor antagonist, and is considered to be a
potent anti-emetic agent in the control of chemotherapy-induced
nausea and vomiting. Its main effect is to reduce the activity of
the vagus nerve, which is a nerve that activates the vomiting
center in medulla oblongata [2]. Granisetron is a well-tolerated
drug, and breaks down slowly, staying in the body for a long
time. It is broken down by the liver’s cytochrome P450 system
and removed from the body by the liver and kidneys. Its
metabolism involves N-demethylation and aromatic ring oxida-
tion followed by conjugation.
However, higher dose and prolonged exposure of drug may
cause some mild and long-term side effects in a subset of patients.
Therefore, it is necessary to establish fast and sensitive analyticallsevier B.V. All rights reserved.
Figure 1 Chemical structure of Granisetron.
R. Jain, R. Sharma444method for detection and quantiﬁcation of Granisetron in biolog-
ical matrix for clinical, toxicological and pharmacological studies.
The widespread use of this compound also requires analytical
method to assay the drug in pharmaceutical formulations and
doses form. Several techniques have been explored for deter-
mination of Granisetron in pharmaceutical formulation and
biological ﬂuids such as high-performance liquid chromato-
graphy [3–6], potentiometric liquid membrane sensor [7],
high performance thin layer chromatography [8] and liquid
chromatography tandem mass spectrometry [9–11]. Although
spectrophotometry and chromatography are the most com-
monly employed techniques, but the demand of expensive and
sophisticated instrumentation, highly skilled personnel and
time consuming extraction puriﬁcation approaches prior to
ﬁnal analysis restrict their use in routine analysis. Since the last
decade, electroanalytical techniques have been widely used in
the ﬁeld of pharmaceutical analysis [12–18]. These techniques
have been found more selective, inexpensive, time saving and
do not require time consuming puriﬁcation steps after extrac-
tion, when compared with other analytical techniques [3–11].
However, no electroanalytical methods have yet been reported
for the quantiﬁcation of Granisetron in pharmaceutical formu-
lation and human plasma. This work describes an analytical
method with acceptable analytical characteristic of suitability
and reliability for detection and quantiﬁcation of Granisetron in
pharmaceutical formulation and human plasma.2. Experimental
2.1. Reagents and chemicals
Granisetron hydrochloride standard (99.20%) was kindly pro-
vided by Veeda Clinical Research Pvt. Ltd., Ahmedabad (India).
Tablets containing Granisetron hydrochloride (Graniforces,
1 mg/Tab) manufactured by Discovery Mankind were obtained
from commercial source. Ultra pure water was obtained from
Milli-Q puriﬁcation system (Millipore Corp., Milford, MA,
USA) and used throughout the studies. Phosphate buffer in
the pH range 2.0–12.0 was prepared in ultra pure water and used
without ﬁltration. All chemicals used were of analytical reagent
grade and employed without further puriﬁcation. Drug free
human blood plasma lots anti-coagulated with sodium heparin
were procured from Radha Swami blood bank, Gwalior, India.
These plasma lots were preserved at 20 1C in freezer and used
after gentle thawing at room temperature.
2.2. Instrumentation and electroanalytical methods
Electrochemical measurements were performed using a m Autolab
Type III potentiostat-galvanostat (Eco-Chemie B.V., Utrecht, The
Netherlands) with 757 VA computrace software. The electrodes
utilized in the study were Hanging Mercury Drop Electrode
(HMDE) as a working electrode, platinum wire as an auxiliaryelectrode and Ag/AgCl (3M KCl) as a reference electrode. All pH
measurements were performed on Decible DB-1011 digital pH
meter ﬁtted with a glass electrode as a working and saturated
calomel electrode as a reference, which was previously standar-
dized with buffer solutions of known pH. The electrochemical
behavior of Granisetron hydrochloride was studied using square-
wave cathodic adsorptive stripping voltammetry (SWCAdSV) and
cyclic voltammetry. The voltammetric experiments were carried
out at room temperature using 0.2 M phosphate buffer as
supporting electrolyte. For electrochemical measurement a volume
of phosphate buffer 9.9 mL and 0.1 mL analyte solution was
added to the electrochemical cell and purged with pure nitrogen
for 25 s. The required accumulation potential (Eacc) was applied to
the working electrode for a selected accumulation time (tacc), while
the solution was stirred continuously at 2200 rpm. The stirring
was stopped and after equilibrium time of 10 s, a negative-going
potential scan was initiated using the parameters those are
reported in Section 3.4.
2.3. Preparation of standard and test solutions
Standard stock solution of Granisetron hydrochloride (500 mg/
mL) was prepared in methanol and further diluted with phos-
phate buffer to achieve a ﬁnal concentration (100 ng/mL) in
the working range. Ten tablets of Granisetron (Graniforces,
1 mg/Tab) were ground to ﬁne powder and mixed well. Sufﬁ-
cient amount of powder equivalent to 5 mg of Granisetron was
taken for preparation of a stock solution (500 mg/mL) into
10 mL volumetric ﬂask and the volume was made up to mark
with methanol. This solution was vortexed and sonicated for
5 min to dissolve all contents of tablets properly. Clear super-
natant liquid was withdrawn and diluted with phosphate buffer
for preparation of test solutions in the calibration range. Stock
and test solutions were stored at 2–8 1C in refrigerator until
analysis.
2.4. Preparation of plasma calibration and quality control samples
Standard stock solution of Granisetron (1 mg/mL) was pre-
pared by dissolving pure compound in methanol. Intermediate
solutions were prepared from stock solution using a mixture of
methanol/water (50:50, v/v) as a diluent. Working solutions
were prepared from intermediate solutions using the same
diluent, at proposed concentration levels of 0.50–2.25 mg/mL.
Plasma calibration and quality control (QC) samples were
prepared by 10% spiking of respective working solutions in
blank plasma. The ﬁnal methanol content of all calibrators
and quality control samples was less than 5%.
2.5. Extraction techniques
Solid-phase extraction (SPE) technique was used to extract
Granisetron from spiked human plasma samples. A volume
of 0.5 mL each of calibrator and quality control samples was
transferred to 1.5 mL pre-labeled rivals. Then 0.2 mL phos-
phate buffer (pH 2.5) was added to each sample, vortexed
for 1 min and centrifuged at 4800 rpm for 5 min. SPE was
performed using oasis mixed mode cation-exchanger (MCX)
cartridges (30 mg/cc), a vacuum manifold device and a vacuum
source. SPE cartridges were conditioned with 1 mL of methanol
and equilibrated with 1 mL of phosphate buffer (pH 7.0).
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cartridges and passed through the beds at a constant ﬂow rate
of 1 mL/min. The cartridges were washed with 1 mL of water to
remove excess of matrix contents and allowed to dry for 30 s.
The analyte was eluted with 1 mL of methanol and analyzed
using square-wave and cyclic voltammetry.Figure 2 Cyclic voltammograms of Granisetron (100 ng/mL) at
scan rate 25–200 mV/s (A) and plot of scan rate (u, mV/s) vs. peak
current (Ip, mA) (B).
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Figure 3 Square-wave voltammograms of Granisetron (175 ng/mL)
at tacc 0.0 s (curve b), tacc 50 s (curve c) and cyclic voltammograms at
tacc 0.0 s (curve e), tacc 50 s (curve f) and blank (curves a & d).3. Results and discussion
3.1. Effect of pH and electrolytes
The shape and characteristics of voltammograms depend on
various electrolytes and pH of the medium. Therefore, effects of
various electrolyte solutions such as phosphate, acetate, borate,
Britton–Robinson and potassium chloride (KCl) on redox
behavior of Granisetron were examined. Granisetron showed
electroactivity in phosphate buffer solution. The effect of pH on
the reduction peak current was also studied in pH range of 2.5–
12.0 at constant concentration. With the rise in pH the peak
current increased up to pH 6.5, after then redox peak current
began to decrease due to pH dependence of half wave potential
which indicates the involvement of protons in the electrode
process and ﬁnally dislocated in alkaline pH due to lower number
of available protons. Thus, phosphate buffer (pH 6.5) was
selected for the study purpose. With the rise in pH peak potential
was also shifted towards more negative potential, which indicated
the existence of a protonation reaction coupled with the Granise-
tron hydrochloride electrode process. The linear dependence
of peak potential on pH can be expressed by the following
expression:
EpðmVÞ ¼4:5437pH120:2707; r¼ 0:9750 ð1Þ
3.2. Cyclic voltammetric behavior
Investigation of CV at different scan rates (u, mV/s) can
provide information involving electrochemical mechanism.
Granisetron exhibited one well-deﬁned cathodic peak in the
potential range from 1.3 to 1.5 V (vs. Ag/AgCl) at all
concentration levels. The absence of any oxidation peak in the
anodic side of the reverse scan indicated that the reduction is
totally irreversible. The inﬂuence of scan rate (u, mV/s)
on the peak current (Ip,A) was studied in the range of
25–200 mV/s, resulting in a linear relationship (r¼0.9946,
n¼8) between Ip and u with a slope of 0.0128. It was found
that peak current increased with increasing scan rate (Fig. 2)
and peak potential shifted toward more negative potential.
The dependence of peak current and peak potential on scan
rate can be expressed by following expressions:
IpðmAÞ ¼ 0:0128uðmV=sÞ þ 0:2146; r¼ 0:9946 ð2Þ
EpðmVÞ ¼0:0009uðmV=sÞ1:4761; r¼ 0:9967 ð3Þ
3.3. Square wave cathodic adsorptive stripping voltammetry
(SWCAdSV)
Different parameters affecting the adsorptive stripping response
of Granisetron in phosphate buffer medium at the HMDE wereexamined to achieve a high sensitivity for their detection and
quantiﬁcation. These parameters included various experimental
and instrumental variables such as accumulation time (tacc),
accumulation potential (Eacc), frequency (f), scan increment (Ds),
pulse amplitude (DEsw) etc.3.3.1. Effect of accumulation time
The analyte accumulation at the working electrode is a crucial
step to achieve a high sensitivity for an electroanalytical
quantitative method. Cathodic adsorptive stripping voltammetric
peak height of Granisetron depends on the tacc, suggesting an
effective adsorption on the HMDE surface. The peak current
increased linearly up to tacc 50 s after those peak current remained
constant due to saturated adsorption of Granisetron on the
Figure 4 The plot of Eacc/V vs. peak current (Ip) of Granisetron (100 ng/mL) in the potential range from 0.0V to 0.9 V (vs. Ag/AgCl).
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stripping analysis was advantageous over that observed at non
stripping techniques. At tacc 50 s, Granisetron showed peak
current enhancement of 4.45% at square-wave voltammetry
(Fig. 3, curve c) and 5.33% at cyclic voltammetry (Fig. 3, curve
f) as compared with the non stripping techniques (Fig. 3, curves b
and e). Hence tacc 50 s was selected as an optimum for the study
purpose.
3.3.2. Effect of accumulation potential
The inﬂuence of Eacc on the peak current of Granisetron
was also examined over the potential range from 0.1 to
0.9 V (vs. Ag/AgCl). Peak current increased linearly with
increasing Eacc (Fig. 4). At more negative Eacc peak current
increased due to strongly adsorption of Granisetron at the
HMDE. Maximum peak current was achieved at Eacc 0.9 V,
which can be expressed by following expression:
IpðmAÞ ¼4:1800EaccðVÞ þ 3:1333; r¼ 0:9753 ð4Þ
3.3.3. Effect of frequency, scan increment and pulse amplitude
Frequency was varied from the 10 Hz to 90 Hz with Ds 10 mV/s,
DEsw 50 mV/s and tacc 50 s. Peak current increased linearly with
frequency, but frequency 50 Hz was chosen to improve the
sensitivity without any distortion of the peak or the baseline.
Effect of the Ds on adsorptive cathodic peak current of
Granisetron was studied; enhancement of the peak current
achieved on the Ds 2–20 mV/s. When using Ds 20 mV/s higher
current was observed and a distortion and enlargement of the
peak occurred. This peak distortion makes difﬁcult to measure
the peak current accurately. The Ds 10 mV/s presented a better
voltammetric peak, that is why used in the present study. The
cathodic peak current for Granisetron was evaluated as a
function of the DEsw 15–50 mV/s in the conditions described
above. The peak current increased linearly with increasing
DEsw. At DEsw 50 mV/s peak current was found to be sharper
and deﬁned; hence DEsw 50 mV/s was ﬁxed for the study
purpose.
3.4. Method validation
Validation of the proposed method to assay of Granisetron
hydrochloride in human matrix and drug product was done as
per USFDA and ICH guidelines [19,20]. The proposed methodwas validated using the following criteria: system suitability,
speciﬁcity, recovery, linearity, reproducibility and ruggedness.
3.4.1. System suitability
The aim of the system suitability experiment is to ensure that the
performance of the analytical system (including instrument,
reagents, electrodes and analysts) is adequate for the intended
analysis. After optimization of operational parameters system
suitability experiment was performed. Six replicate readings of
Granisetron (100 ng/mL) were taken by individually sample
preparation. Relative standard deviation 1.24% was obtained
using data generated from six replicate readings, indicating that
the analytical system is adequate for the intended analysis.
3.4.2. Speciﬁcity
Speciﬁcity is the ability of the analytical method to measure the
analyte in the presence of other interferences with acceptable
accuracy and precision. The speciﬁcity of the assay procedure for
estimation of Granisetron hydrochloride was evaluated in the
presence of different concentrations of various inactive ingredi-
ents (excipients) of tablet like lactose monohydrate, microcrystal-
line cellulose, hydroxypropylmethyl cellulose, opadry ys-1r-7003,
sodium starch glycollate, magnesium stearate. Interferences were
not found at the reduction potential of Granisetron hydrochlor-
ide. The response of the analyte in the presence of excipients was
also compared with the response of the pure Granisetron. It was
found that assay result does not change. Thus, the proposed
procedure can be considered speciﬁc.
3.4.3. Recovery
Formulation product recovery experiment was carried out at
three different concentration levels in six replicates. The effects
of various tablets inactive ingredients on recovery were also
studied. For this known concentration of excipient solutions
were mixed with deﬁnite amount of pre-analyzed formulations
of the drug and the mixtures were analyzed as before. It was
noticed that none of these interfered in the determination at
the levels normally found in dosage forms. The results of
recovery study were found to be quantitative, which are listed
in Table 1.
Absolute recovery (in spiked human plasma) was per-
formed by comparing extracted quality control (QC) samples
of three different concentration levels, LQC (75 ng/mL), MQC
(125 ng/mL) and HQC (200 ng/mL) in six replicates with un-
extracted samples of the same levels. The results indicated that
Cathodic adsorptive stripping voltammetry of an anti-emetic agent Granisetron 447the mean recovery of Granisetron from human plasma was
58.69% (Table 1), which was enough for determination of
Granisetron precisely in human matrix.3.4.4. Linearity
The relationship between the reduction peak current (Ip, mA)
and the concentration of Granisetron (ng/mL) was examined
by SWCAdSV at HMDE surface. The reduction peak current
was proportional to the Granisetron concentration. An excel-
lent linearity was observed over a wide concentration range of
50–200 ng/mL (seven concentration levels). The calibrationTable 1 Recovery of Granisetron from human matrix
and pharmaceutical formulation.
Recovery level Human
matrix
Formulation
Recovery level-1 [LQC]a (%) 58.67 98.70
Recovery level-2 [MQC]a (%) 58.80 98.94
Recovery level-3 [HQC]a (%) 58.59 99.07
Mean recovery (%) 58.69 98.90
CV of mean recovery (%) 0.18 0.19
RSD (%) 0.106 0.188
aRecovery at each level represents the average of six observa-
tions (n¼6).
Table 2 Accuracy of standard linearity and extracted
plasma calibration curve of Granisetron.
Calibration standard Accuracy (%)
Aqueous Plasma
CS-01 88.58 83.20
CS-02 104.22 103.07
CS-03 107.19 107.80
CS-04 104.59 103.84
CS-05 105.44 102.53
CS-06 103.47 102.74
CS-07 99.08 99.40
CS-08 – 99.47
Table 3 Square-wave voltammetric method validation parameter
Parameters Aqu
Slope 0.0
Standard deviation 0.0
Intercept 0.0
Standard deviation 0.1
Correlation coefﬁcient 0.9
Standard error of estimation 0.1
Sum of squares of regression 16.8
Sum of squares of residuals 0.0
Limit of detection (ng/mL) 13
Limit of quantiﬁcation (ng/mL) 41plot resulted in a straight line, which can be expressed by
following expression:
IpðmAÞ ¼ 0:0310ðng=mLÞ0:0150; r¼ 0:9953 ð5Þ
Limit of detection (LOD) and limit of quantiﬁcation (LOQ)
estimated as 3S/m and 10S/m were found to be 13.63 ng/mL and
41.29 ng/mL respectively. Where, ‘‘S’’ is the standard deviation
and ‘‘m’’ is the slope of the calibration curve. In aqueous
solution, accuracy of all calibration standards was within
85–115%, except LLOQ, where it was 80–120% of the theore-
tical value (Table 2). The analytical characteristics for standard
linearity and related validation parameters were also calculated
and are summarized in Table 3. Representative square-wave
cathodic adsorptive voltammograms and plot of concentration
(mg/mL) vs. peak current (Ip, mA) are shown in Fig. 5.
3.4.5. Reproducibility and ruggedness
For quantiﬁcation of analyte, the developed analytical method
should be reproducible and rugged. The high sensitivity of
the adsorptive voltammetry is accompanied by reproducibility.
The reproducibility was evaluated from six repeated measure-
ments of the electrochemical signal of Granisetron standard
solution (100 ng/mL). The precision of the developed method in
terms of the relative standard deviation (% RSD) was 1.17%.
Ruggedness of the voltammetric method was veriﬁed by
analyzing six samples of a Granisetron standard solution (100 ng/
mL) by two different analysts by SWCAdSV method using the
same instrument on different days. Overall RSD value 1.63% was
obtained between the two sets of data, proving the ruggedness of
the proposed method.
3.5. Analytical applications of the proposed methodology
3.5.1. Biological matrix analysis
This validated method was successfully applied to the determina-
tion of Granisetron in spiked human plasma using solid-phase as
an extraction technique. An excellent calibration curve was
observed over a wide concentration range of 50–225 ng/mL with
a correlation coefﬁcient (r) of 0.9966. The calibration plot
resulted in a straight line, Ip(mA)¼0.0099 (ng/mL)þ0.0885.
The LOD and LOQ were found to be 11.75 and 35.61 ng/mL
respectively, indicating that the level of Granisetron in humans for standard linearity and extracted plasma calibration curve.
eous linearity Plasma
calibration curve
310 0.0099
010 0.0002
150 0.0885
280 0.0353
953 0.9966
258 0.0384
175 2.5757
791 0.0088
.63 11.75
.29 35.61
Figure 5 Square-wave voltammograms of standard solution of
Granisetron at concentration levels, 50–200 ng/mL (A, curves
b–h), blank solution (A, curve a) and plot of concentration vs.
peak current (B).
Figure 6 Square-wave voltammograms of Granisetron at con-
centration levels, 50–225 ng/mL (A, curves b–i), blank solution
(A, curve a) and plot of concentration vs. peak current (B),
extracted from human plasma through SPE.
Table 4 Determination of Granisetron in tablets (Graniforces) a
Formulation products
Amount
added (ng)
Amounta
found (ng)
Accuracy (%) CV (%)
75 74.14 98.85 1.33
125 123.99 99.19 1.05
175 173.55 99.17 1.29
aAmount found represents the average of six observations (n¼6).
R. Jain, R. Sharma448matrix can be determined precisely. Representative SWCAdS
voltammograms of different concentrations of Granisetron
spiked in human plasma are depicted in Fig. 6A (curves bi);
its calibration curve is depicted in Fig. 6B. No interfering peaks
were observed in the blank plasma samples within the studied
potential range (Fig. 6A, curve a). The results indicated that
the analytical method is accurate, as the accuracy was within
the acceptance criteria of 715% except LLOQ where it was
720% of their nominal value (Table 2); whereas precision was
also within the acceptance criteria (15%) at all concentration
levels of the theoretical value. Various statistical parameters for
linear regression equation were also calculated and are listed in
Table 3.
3.5.2. Pharmaceutical formulation analysis
The optimized procedure was successfully applied to the determi-
nation of Granisetron hydrochloride in drug product (commercial
dosage form, tablet Graniforces). There was no need for ﬁltration
of tablets extracts from un-dissolved excipients; just dilution of an
aliquot from the supernatant layer with the supporting electrolyte
was required before measurement. Voltammograms of Granise-
tron hydrochloride in phosphate buffer exhibit well deﬁned
cathodic peak. The current was mainly adsorption-controlled
and proportional to the concentration. The good linearity of the
calibration graph and the negligible scatter of the experimental
points are clearly evident by the correlation coefﬁcients. The mean
recovery of Granisetron found to be 98.90% proved the applic-
ability of the proposed method (Table 1). The assay results
obtained by the proposed method are listed in Table 4, indicating
that method could be applied to the determination of Granisetron
in drug product. Therefore, the proposed procedure may be
applicable for analysis of this and other similar formulation
products containing Granisetron.
4. Conclusion
The electrochemical reduction of Granisetron under the condi-
tions described in this work is an irreversible process con-
trolled by adsorption. Solid-phase extraction technique was
employed for the extraction of Granisetron from human plasma.
This method does not require sophisticated instrumentation and
large setup for toxicological and pharmacokinetic studies. The
proposed method does not required additional step like, eva-
poration after extraction of analyte from biological matrix.
The high percentage of recovery showed that the com-
pounds was completely extracted from tablet formulation and
the results indicated that the proposed method is sensitive,
accurate, precise and cost effective as well as time savingnd human plasma by the proposed voltammetric methods.
Plasma samples
Amount
added (ng)
Amounta
found (ng)
Accuracy (%) CV (%)
75 73.24 97.65 1.83
125 123.77 99.02 1.50
200 198.10 99.05 1.59
Cathodic adsorptive stripping voltammetry of an anti-emetic agent Granisetron 449for routine analysis in quality control, assay of Granisetron
in pharmaceutical formulation, doses form and pure form.
Thus, this method can be adopted for routine analysis in
quality control and research and development laboratories.
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